Listen on the go
CORRECT!
Next question
touchIMMUNOLOGY touchIMMUNOLOGY

Start Learning

Touch Loading image
Epinephrine 1mg Nasal Spray Gains Approval for Type I Allergic Reactions in Children
JOURNALS
Start Learning
Epinephrine 1mg Nasal Spray Gains Approval for Type I Allergic Reactions in Children Over 4 Years, who Weigh 15 to <30 kg
touchEXPERT OPINIONS
Start Learning
Primary biliary cholangitis: Appraising the changing therapeutic landscape
CE/CME ACCREDITED
European Commission approval of upadacitinib 15 mg for the treatment of giant cell arteritis in adult patients
JOURNALS
Start Learning
European Commission approval of upadacitinib 15 mg for the treatment of giant cell arteritis in adult patients
CONFERENCE HUB
Start Learning
Key data on pain and prognosis: Clinical insights and implications
JOURNALS
Start Learning
Breakthroughs in MASH: Highlights from EASL 2024
New data from IMPACT-PLuS suggests early peanut oral immunotherapy has a lasting immunologic impact in children
JOURNALS
Start Learning
New data from IMPACT-PLuS suggests early peanut oral immunotherapy has a lasting immunologic impact in children
www.touchimmunology.com
JOURNALS
Start Learning
FDA approves bimekizumab for psoriatic arthritis, ankylosing spondylitis and axSpA
Musculoskeletal AI image
JOURNALS
Start Learning
Artificial Intelligence in Musculoskeletal Medicine: A Scoping Review
touchMDT
Start Learning
Navigating the management of cholestatic pruritus in patients with PBC: Insights from the multidisciplinary team
CE/CME ACCREDITED
3d medical x ray of knee pain with arthritis inflammation and tendon injury, copy space
JOURNALS
Start Learning
Clinical Approach to the Care of Patients with Immune Checkpoint Inhibitor-associated Inflammatory Arthritis

to view Favourites, Keep Notes and Track CME Credits

Favourites
RMDs: What to Expect in 2025
View
Key data on pain and prognosis: Clinical insights and implications
View
New data from IMPACT-PLuS suggests early peanut oral immunotherapy has a lasting immunologic impact in children
View
Epinephrine 1mg Nasal Spray Gains Approval for Type I Allergic Reactions in Children Over 4 Years, who Weigh 15 to <30 kg
View
Artificial Intelligence in Musculoskeletal Medicine: A Scoping Review
View
European Commission approval of upadacitinib 15 mg for the treatment of giant cell arteritis in adult patients
View
Medics For Rare Disease – New Year, New Strategy
View
Navigating the management of cholestatic pruritus in patients with PBC: Insights from the multidisciplinary team
View
A Career in Endoscopy: 5 insights from UEG Lifetime Achievement Awardee – Paul Fockens
View
Breakthrough treatments for hereditary angioedema revealed at EAACI 2024
View
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup